


Patient: [REDACTED]
 DOB: [REDACTED] Age: [REDACTED] Gender: [REDACTED]
 Patient Identifiers: [REDACTED]
 Visit Number (FIN): [REDACTED]

Client: [REDACTED]
 Physician: [REDACTED]

ARUP Test Code: 2013612
 Collection Date: 11/12/2017
 Received in lab: 11/13/2017
 Completion Date: 11/14/2017

Patient History *

<u>Collection Date</u>	<u>Infliximab Activity (IFX) ug/mL</u>	<u>Accession Number</u>
11/12/2017	10.17	17-316-400346
10/2/2017	8.29	17-275-401767



Cutoff values are 0.65 ug/mL for infliximab.

*Consecutive test results are displayed on this chart; however, this result set may be incomplete due to variations in the demographic information submitted for prior tests. If the information on this chart appears incomplete, please consult this patient's prior charts.



Patient: [REDACTED]
 ARUP Accession: 17-316-400346

Infliximab and Infliximab-dyyb with Reflex to Antibody

Patient: [REDACTED] | Date of Birth: [REDACTED] | Gender: [REDACTED] | Physician: [REDACTED]
Patient Identifiers: [REDACTED] | Visit Number (FIN): [REDACTED]

Interpretive Comments

Interpretive Data: This test measures the capacity of infliximab to neutralize TNF-alpha activity. Additionally, infliximab neutralizing antibodies (NAb) are titered (reporting the highest dilution of patient sera in which NAb activity is detected).

This test is used to evaluate secondary response failures to infliximab therapy. Secondary response failure is defined as loss of clinical response after initial improvement of clinical signs and symptoms. Therapeutic decision should rest on both the clinical response and the knowledge of the fate of the drug including the emergence of immunogenicity in individual patients.

Circulating infliximab levels have been shown to vary considerably between patients. These differences relate to route and frequency of administration and patient-related features such as age, gender, weight, drug metabolism, and concomitant medications such as methotrexate and other immunosuppressants.

If Infliximab drug level is not detected, then Infliximab Neutralizing Antibody Titer will be added

IF Infliximab Activity is...	AND Infliximab Neutralizing Antibody Titer is...	THEN...
Not Detected	Not Detected	A higher dosage of infliximab or shortening the dosing interval may be appropriate.
Not Detected	1:20 or greater	A change to another anti-TNF-alpha drug may be appropriate.
0.65 ug/mL or greater	Not Applicable	A change to another type of therapy (not targeting TNF-alpha) may be appropriate, if the patient did not respond adequately to infliximab therapy.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: www.aruplab.com/CS.



Patient: [REDACTED]
ARUP Accession: 17-316-400346